Send me real-time posts from this site at my email
Motley Fool

Why Harmony Biosciences Stock Is Up 15% Today

What happened

Shares of Harmony Biosciences Holdings (NASDAQ: HRMY) were trading more than 15% higher as of midday Tuesday following news that the company is to become part of the S&P 600 small-cap stock index.

So what

S&P Global's S&P Dow Jones Indices division made the announcement after yesterday's close, reporting that along with LendingTree, Harmony Biosciences would officially become an S&P 600 constituent before this coming Friday's opening bell rings.

Image source: Getty Images.

Aside from being something of an accolade, being chosen as part of an index means any institution that manages an S&P 600 index-based mutual fund or exchange-traded fund will now be adding this stock to their investment pools. This en masse buying translates into bullish buying pressure on shares. Today's frenzied buying is the market's anticipation of Friday's big impending buy-in.

Now what

Credit must be given where it's due. Harmony Biosciences Holdings has earned its place within the S&P 600. Last year's top line of $159.7 million was the first meaningful revenue the young company has produced, driven by the approval of its Wakix (pitolisant) tablets for the treatment of narcolepsy. Yet, it was enough to pull Harmony out of the red and into the black... at least on an operating basis. This year's projected top-line growth of 92% should improve upon last year's adjusted per-share profit of $0.21 to $1.10, en route to next year's estimated (operating) per share earnings of $2.84.

The biopharma outfit is clearly on a growth track. And even with today's big rally, shares are still down 16% from November's post-IPO peak. In a bigger-picture sense, however, there's still plenty of room for more upside.

In light of the sheer strength of today's pop, though, the impending inclusion in the S&P 600 isn't quite enough to merit stepping in now.

10 stocks we like better than Harmony Biosciences Holdings, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Harmony Biosciences Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 17, 2021

James Brumley has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends S&P Global. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue